A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986322 in Healthy Participants Including an Open-label Assessment of Food and pH Effects on Relative Bioavailability of BMS-986322
Latest Information Update: 01 Jun 2022
At a glance
- Drugs BMS 986322 (Primary) ; Famotidine
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 26 May 2022 Status changed from active, no longer recruiting to completed.
- 30 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2019 New trial record